Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
Background and aims: Various attempts have been made to support recovery following optic neuritis (ON), but the respective trials have mostly been negative. The aim of this study was to determine whether disease-modifying treatment (DMT) following ON as first manifestation of relapsing-remitting mul...
Main Authors: | Steffen Pfeuffer, Laura Kerschke, Tobias Ruck, Leoni Rolfes, Marc Pawlitzki, Philipp Albrecht, Heinz Wiendl, Sven G. Meuth |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-03-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756286421997372 |
Similar Items
-
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
by: Steffen Pfeuffer, et al.
Published: (2022-09-01) -
Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
by: Ester Riepl, et al.
Published: (2018-01-01) -
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
by: Carlo Tornatore, et al.
Published: (2022-02-01) -
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
by: Laura Bierhansl, et al.
Published: (2019-12-01) -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
by: Leoni Rolfes, et al.
Published: (2023-04-01)